Drug Profile

VTP 850

Alternative Names: VTP-850

Latest Information Update: 19 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vaccitech
Developer Barinthus Biotherapeutics
Class Antineoplastics; Cancer vaccines; Immunotherapies
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II Prostate cancer

Most Recent Events

07 Aug 2025 Adverse events data from a phase I/II trial in Prostate cancer released by Barinthus Biotherapeutics
07 May 2025 VTP 850 is available for licensing as of 07 May 2025. https://www.barinthusbio.com/
05 Feb 2025 Barinthus Biotherapeutics terminates phase I/II trial for Prostate cancer (Recurrent, Second-line therapy or greater) in USA (IM, IV) following completion of the phase 1 portion (NCT05617040)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com